TLDR
- Immutep shares plummeted approximately 80% on Friday following the termination of its Phase III lung cancer study due to futility.
- An Independent Data Monitoring Committee advised discontinuing the TACTI-004 trial testing eftilagimod alfa (efti) in first-line NSCLC patients.
- Baird cut its rating from Outperform to Neutral and reduced the price target from $7.00 down to $1.00.
- Citizens downgraded shares from Market Outperform to Market Perform while eliminating NSCLC revenue forecasts entirely.
- Share turnover surged past 11 million units — a dramatic increase from the typical daily volume of approximately 154,000 shares.
Immutep (IMMP) experienced a devastating roughly 80% decline on Friday following the company’s disclosure that it would terminate its TACTI-004 Phase III clinical study. The trial had been testing eftilagimod alfa, commonly referred to as “efti,” in individuals with first-line non-small cell lung cancer (NSCLC).
The termination followed guidance from the Independent Data Monitoring Committee (IDMC), which assessed both safety and efficacy metrics and determined the study should cease due to futility. Essentially, the available evidence indicated the therapy would not achieve its intended objectives even with continuation.
Company CEO Marc Voigt expressed significant disappointment with the findings. “We are very disappointed and surprised with the outcome of the futility analysis, in light of efti’s performance in every other clinical trial,” he remarked in an official company statement.
Immutep confirmed it would cease all new patient recruitment and initiate a systematic shutdown of the trial, which includes completing patient monitoring and closing study sites according to regulatory standards.
Wall Street Responds with Rating Cuts
The market’s response was immediate and severe — matched by equally quick moves from Wall Street analysts.
Baird’s Colleen Kusy lowered her rating on IMMP from Outperform to Neutral while slashing the price objective from $7.00 to just $1.00. The shares were trading near $2.76 when the downgrade was issued, significantly above the revised target. Baird indicated there’s no obvious pathway forward for efti given these trial results.
Citizens’ Reni Benjamin similarly reduced his rating from Market Outperform to Market Perform. Benjamin stripped out all NSCLC-related revenue assumptions from his financial model for the company.
Both research firms anticipate IMMP will track broader market movements until substantive data emerges from other randomized clinical trials in the pipeline.
Prior to Friday’s collapse, IMMP stock had declined roughly 3.5% year-to-date but had posted gains of 55% over the trailing twelve months. That impressive rally has now been virtually eliminated.
The Road Ahead for Immutep
There is one potential positive development for the biotechnology firm: eliminating the TACTI-004 study removes a significant expense from the balance sheet. Immutep now projects its cash reserves will last substantially beyond the previously communicated Q2 2027 projection. The company plans to provide refined cash guidance after completing the trial shutdown process.
Immutep indicated it will maintain focus on advancing other programs in its development pipeline. Nevertheless, given that NSCLC represented the flagship indication, the company’s strategic options appear markedly constrained.
Share volume on Friday illustrated the panic. Over 11 million shares traded during the morning session alone — versus a three-month daily average of roughly 154,000 shares. That represents approximately 70 times typical trading activity.
The consensus rating on IMMP currently stands at Hold, reflecting two Hold ratings. No average price target is presently available for the stock.
